In 2023, Detarya et al. reported that tiliacorinine induces apoptosis in cholangiocarcinoma cells by downregulating the anti-apoptotic proteins Bcl-xL and XIAP, activating caspase-3, caspase-9, and PARP, and inhibiting phosphorylated Akt and STAT3. Here, AKT1 is linked to cholangiocarcinoma.